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Hemolytic-uremic syndrome (HUS) is a microvasculature disorder leading to microangiopathic hemolytic anemia,
thrombocytopenia, and acute renal failure. Most cases of HUS are associated with epidemics of diarrhea caused
by verocytotoxin-producing bacteria, but atypical cases of HUS not associated with diarrhea (aHUS) also occur.
Early studies describing the association of aHUS with deficiencies of factor H suggested a role for this complement
regulator in aHUS. Molecular evidence of factor H involvement in aHUS was first provided by Warwicker et al.,
who demonstrated that aHUS segregated with the chromosome 1q region containing the factor H gene (HF1) and
who identified a mutation in HF1 in a case of familial aHUS with normal levels of factor H. We have performed
the mutational screening of the HF1 gene in a novel series of 13 Spanish patients with aHUS who present normal
complement profiles and whose plasma levels of factor H are, with one exception, within the normal range. These
studies have resulted in the identification of five novel HF1 mutations in four of the patients. Allele HF1Dexon2,
a genomic deletion of exon 2, produces a null HF1 allele and results in plasma levels of factor H that are 50% of
normal. T956M, W1183L, L1189R, and V1197A are missense mutations that alter amino acid residues in the C-
terminal portion of factor H, within a region—SCR16–SCR20—that is involved in the binding to solid-phase C3b
and to negatively charged cellular structures. This remarkable clustering of mutations inHF1 suggests that a specific
dysfunction in the protection of cellular surfaces by factor H is a major pathogenic condition underlying aHUS.
Hemolytic uremic syndrome (HUS) is a common cause
of acute renal failure in children, leading to substantial
morbidity and mortality (reviewed in Ruggenenti and
Remuzzi 1998). HUS is characterized by a triad of symp-
toms—microangiopathic hemolytic anemia, thrombo-
cytopenia and acute renal failure. Typical, epidemic or
diarrhea-associated HUS is most common in infants and
young children. In the majority of the cases, it is asso-
ciated with the 0157:H7 strain ofEscherichia coli,which
produces a powerful exotoxin (either verocytotoxin or
verotoxin). Other possible triggers of the disease are vi-
ruses and neuraminidase-producing microorganisms.
The outcome of these patients is usually good, with a
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complete recovery of renal function within 2 or 3 wk.
Atypical, non–diarrhea-associated HUS (aHUS) is most
common in older children and adults. The prognosis is
poorer than that in typical HUS, with a high (10%–
30%) mortality. Renal involvement is a constant feature,
and up to 50% of patients may need dialysis. Neuro-
logical symptoms are also common, and sequelae may
persist for several years. Most cases of aHUS are idio-
pathic, but predisposing factors such as anticancer
drugs, immunosuppressive agents, or oral contraceptives
have been reported. aHUS can also develop during either
the third trimester of pregnancy or the postpartum pe-
riod, as well as in association with anti-endothelial an-
tibodies. Although most cases are sporadic, familial cases
of aHUS have been described. In these cases, both au-
tosomal dominant (MIM 134370) and recessive (MIM
235400) modes of inheritance have been reported.
A number of observations, including the recurrence
of the disease in transplanted individuals and the positive
response to plasma exchange in some patients, have
pointed to the involvement of a plasma factor in the
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etiology of aHUS. These facts, together with early re-
ports describing the association of aHUS with deficien-
cies of the plasma protein factor H (Thompson and Win-
terborn 1981; Pichette et al. 1994; Ohali et al. 1998;
Rougier et al. 1998), led to the decisive linkage studies
by Warwicker et al. 1998, later confirmed by Ying et al.
1999, revealing that the disease segregates with a chro-
mosome 1q32 region that includes the gene encoding
factor H (HF1). Furthermore, in one of the families with
aHUS that are included in these linkage studies, a mis-
sense mutation that had no effect on the levels of factor
H was found in the HF1 gene, strongly supporting a
role for factor H in the pathogenesis of aHUS.
Factor H is a plasma protein (molecular mass 155,000
daltons) composed of 20 repetitive units of 60 amino
acids called “short consensus repeats” (SCR) (Ripoche
et al. 1988), also known as “complement control pro-
tein” (also known as “CCP”) modules. Factor H is en-
coded by a single gene located on human chromosome
1q32, within the RCA (regulators of complement acti-
vation) gene cluster (Rodrı´guez de Co´rdoba et al. 1985;
Weis et al. 1987). Five additional factor H–related hu-
man plasma proteins have been identified and shown to
be encoded by five genes, FHR1–FHR5, closely linked
to the HF1 gene (Zipfel and Skerka 1994; Zipfel et al.
1999; Rodrı´guez de Co´rdoba et al. 1999; McRae et al.
2000). Factor H controls activation of the alternative
pathway of complement in fluid phase and on cellular
surfaces. It binds to C3b, accelerates the decay of the
alternative-pathway C3-convertase and acts as a cofac-
tor for the factor I–mediated proteolytic inactivation of
C3b (Weiler et al. 1976; Whaley and Ruddy 1976; Pang-
burn et al. 1977). Factor H can also interact with polyan-
ionic molecules (sialic acids or glycosaminoglycans) on
certain cellular surfaces, conferring to them resistance to
damage as a consequence of complement activation
through the alternative pathway (Meri and Pangburn
1990; Pangburn et al. 1991). Complete factor H defi-
ciency leads to a situation of hypocomplementemia that
increases the risk of infection by pathogens and that is
usually associated with recurrent infections by pyogenic
microorganisms. In addition, deficiency of factor H has
been associated with systemic lupus ertythematosis, type
II membrane-proliferative glomerulonephritis, collagen
type III glomerulopathy, and, as indicated above, familial
HUS (reviewed in Ault 2000).
To get further insight into the genetic relationship be-
tween aHUS and factor H, we have performed muta-
tional screening of HF1 in a novel series of patients with
aHUS. These studies have been facilitated by previous
work in our laboratory, related both to the organization
of the HF1/FHR1–FHR5 region of the RCA gene cluster
and to the structure of the human HF1 gene. Figure 1a
summarizes the organization of the 1q32 genomic region
containing the humanHF1 gene and FHR1–FHR5 genes
(for genomic sequences of HF1 and of FHR1–FHR5, see
the Entrez Nucleotide Sequence Search Web site). Besides
showing the exon/intron organization of the genes
within this region, figure 1a also illustrates the existence
of a number of large genomic duplications (1.2–38 kb
long; 85%–97% identity) including different exons of
the HF1/FHR1–FHR5 genes. Since two of these genomic
duplications include exons 8/9 and exons 21–23, re-
spectively, of the HFI gene, we took special care in the
design of the PCR primers used to amplify these HF1
exons, so that homologous exons in either the FHR1
gene or the FHR3 gene would not be amplified. Table
1 shows the primer sequences and PCR conditions that
we have used to amplify each of the exons of the HF1
gene from genomic DNA.
Patients included in these studies were selected on the
basis of a single criterion: presenting a clinical history
of HUS of non–diarrhea-associated origin. Chronic renal
failure and/or unsuccessful renal transplantation led
most of them to hemodialysis. Twelve of the patients
have no family history of HUS. In only one of the pro-
bands, HUS11, the death of the mother, as a consequence
of postpartum aHUS, was reported. Our patients have
a normal complement profile, and, with the only excep-
tion of HUS3, they all present with normal plasma levels
of factor H, as determined by ELISA and semiquanti-
tative western blot analyses (table 2). The mutational
analysis of the HF1 gene was performed in genomic
DNA from these patients and their available relatives,
by both SSCP analysis and automatic DNA sequencing
of the HF1 exons. In several of our patients, HF1 se-
quences were also obtained by reverse transcriptase–
PCR using total RNA obtained from peripheral blood
lymphocytes, as described elsewhere (Sa´nchez-Corral et
al. 2000).
In 4 of the 13 patients with aHUS, we identified HF1
mutations that were not found in a sample of 1100
population-matched HF1 control chromosomes (fig.
1b). Patient HUS2 is heterozygous for a GrT substi-
tution at HF1 nucleotide position c.3621 in exon 23.
This mutation results in a tryptophan-to-leucine change,
W1183L, in SCR20. No mutations were found in the
other HF1 chromosome. The W1183L mutation was
identified both in genomic DNA and in RNA obtained
from the lymphocytes of the patient, but not in either
the DNA or the mRNA obtained from his parents, in-
dicating that it is a de novo mutation. Patient HUS3
presented a TrC substitution at nucleotide position
c.3663 in exon 23, apparently in homozygosis. This mu-
tation changes the amino acid valine 1197 to alanine in
factor H SCR20. No additional mutations to V1197A
were found in HUS3. Since levels of factor H in HUS3
were half of normal levels, and since she was also found
to be homozygous at c. 257, c.994, c.1277, c.1492,
c.1551, c.2089, c.2881, and c.3705 HF1 polymorphic
Figure 1 Mutations in factor H in patients with aHUS. a, Organization of the 1q32 genomic region containing the human HF1 gene. Colored
arrows indicate the location and transcriptional orientation of the HF1 gene and the FHR1–FHR5 genes. For each gene, the exon/intron organization
is indicated by vertical bars. Genomic duplications within the region are indicated by colored boxes. These duplications are 1.2–38 kb in size and
present a pairwise nucleotide identity of 85%–97%. The exon/intron organization of the HF1 gene, as well as the nucleotide sequences of the
intronic flanking regions, was determined on the basis of data published by Male et al. (2000) and of data generated in our laboratory by PCR
analysis and sequencing of PAC clones RPCIP704A14355, RPCIP704L20665, RPCIP704M03650, RPCIP704O14608 (authors’ unpublished data).
These data and sequence data generated by the Human Genome Project (clones AL049741, AL049744, AL139418, and AL353809) provided the
genomic sequence for the HF1 gene and the FHR1–FHR5 genes. HF1 comprises 23 exons and spans 194 kb of genomic DNA. Exon 10 does not
contribute to the factor H transcript; it is utilized only in the alternative HF1 transcript that codes for the factor H–like 1 molecule (also known
as “FHL-1”) (Estaller et al. 1991). To amplify each of the HF1 exons present in the factor H transcript, we designed PCR primers to the intronic
flanking sequences (table 1). Primers for exons 8/9 and 21–23 were designed to avoid amplification of homologous exons in the FHR3 gene and
the FHR1 gene, respectively. b, Identification of mutations in the factor H gene in four patients with aHUS. The pedigrees of patients HUS2, HUS3,
HUS11, and HUS12 are shown, as are the chromatograms corresponding to the DNA sequence surrounding the mutated nucleotide for each patient
and family members studied. The positions of nucleotide changes are according to the cDNA sequence reported by Ripoche et al. (1988). The ATG
initiation codon is located at nucleotide position c.74. Amino acid numbering includes the signal peptide. c, Functional domains and mutations in
the factor H molecule. A diagram of the structure of human factor H with the 20 SCR repeats is shown. Functional domains are indicated
schematically. The location of the six missense mutations thus far characterized in patients with aHUS (four of whom reported here) is indicated











1 Signal peptide GACGTTGTGAACAGAGTTAGCTG ACTCCTGTGAAAAGCATCATTAG 181
2 SCR1 GTACATTTAAATAGACACTTTATGC TACACCTAGTTTTCATAAATTTCAC 281
3 SCR2A CCCACTCCTACATAAAATATATTCC CCTATTTACTATCTTAATTATAAACC 171
4 SCR2B TAAACACACATTATGTCAACGTTC GAGAC TTTAAGATATTTTAATGTAAG 206
5 SCR3 TACATACACATATTTTTCACAATAAAC GCAAAAATACTAAAACAGTAAGTG 294
6 SCR4 CCTTTAATTTGCAATAAACATTTTGG TATGTGATAAATTTATAAAGATCCAG 263
7 SCR5 CGGATACTTATTTCTGCATTATCC AAATTTCAGAATTAAGAAATGGGTC 264
8 SCR6 GTTTATTACAGTAAAATTTCTTTATAC CTTCGATCTTTGAAAGTTTTATAC 300
9 SCR7 TGAGCAAATTTATGTTTCTCATTTAC TTAGAAAGACATGAACATGCTAGG 279
11 SCR8 AAAATGTTATTGATCATATGCTTGTC ACTTTTGTGTATCATCTGGATAATC 284
12 SCR9 GTTTATTAGATGACATTAGAAATGAC GGAAAACAGATTTATTTTCATTTTG 280
13 SCR10 TTGGCAATGATTAATTATATATTCTC TCAAAGTTCTAATTCTTATTTCAGC 274
14 SCR11 TATATTGTAAAACAGACAATTTAACC ATACAAAATACAAAAGTTTTGACAAG 289
15 SCR12 AAAACACATACATCATGTTTTCAC GTTGTTACAATAAAAATATTAAACTTTG 292
16 SCR13 AGTTGGTTTGATTCCTATCATTTG ACACACATACCTATTACTTTTCC 277
17 SCR14 ATATTTTTATTTTTTATTTTTTATTATAAC TATTAACCTCATTTGAAAGAATTATG 290b
18 SCR15 GTATTTTATTTGTTTTTAACCCTTTG ATGAATTCTACTATAAACAGAAATTG 277
19 SCR16 TAAATTTATGAGTTAGTGAAACCTG TGGTACCACTTACACTTTGAATG 272
20 SCR17 TTTTAAAGATTTGCGGAACAAATAC CCCACACATTATATAAATAAATTTTG 263
21 SCR18 TTGCTACTCAAAATGAACACTAGG CCTGCTATACTCCCCCAAAATG 274
22 SCR19 TTGTATTTTGATTTGCTCTCACAAC GTGAAATATCAGACTCATCACAGA 296
23 SCR20 ATTTGCATACTACTTAATGTTTTATG AGTTCTGAATAAAGGTGTGCAC 284c
a Analyzed by SSCP on 8% polyacrylamide gels that were run at room temperature and at 4C for 20 h, under constant current. All
fragments also were gel purified and were sequenced in a ABI-PRISM 377 automatic sequencer. All the PCR reactions were done at an
annealing temperature of 57C in 1.5 mM MgSO4.
b A fragment of 477 bp was generated by primers GAAAGTCTATGAGAATACAAGCC and TATTAACCTCATTTGAAAGAATTATG
and then was reamplified with the primers given in the table.
c A fragment of 396 bp was generated by primers TTTATTCAAATCAATATGATGTTTC and AGTTCTGAATAAAGGTGTGCAC and
then was reamplified with the primers given in the table.
sites (to be described elsewhere), we set up experiments
to determine whether she carries a genomic deletion in
HF1 in heterozygosis. Segregation analysis of HF1 poly-
morphisms in her son demonstrated that she carries a
null allele at the c.257 polymorphic site in exon 2 (cod-
ing for SCR1), indicating a partial deletion of the HF1
gene in one of her chromosomes. Although the precise
length of the deletion has not been established, we con-
clude that this deletion results in a null HF1 allele
(HF1Dexon2) that is not transcribed into mRNA. Pa-
tient HUS3 was, therefore, interpreted to be an HF1
hemizygote who, in addition, carries the V1197A mu-
tation in her only functional HF1 allele. Since the nu-
cleotide change involved in the V1197A mutation is one
of the two nucleotide differences that distinguish HF1
exon 23 from FHR1 exon 6, within the large genomic
duplication involving the 3′ end of these two genes (fig.
1a), we suggest that the V1197A mutation could have
originated via a gene-conversion event betweenHF1 and
FHR1.
DNA sequence analysis of HF1 demonstrated that a
third patient, HUS11, is heterozygous for a TrG sub-
stitution at HF1 nucleotide position c.3639 in exon 23.
This mutation results in a leucine-to-arginine change,
L1189R, in SCR20. The mutation was not found in the
father of the patient, suggesting a maternal origin. How-
ever, DNA from the mother, who had died of postpartum
HUS, was not available. Finally, in a fourth patient,
HUS12, HF1 mutational analysis demonstrated a CrT
substitution in heterozygosis at nucleotide position
c.2940 in exon 19. This change results in a threonine-
to-methionine change, T956M, in SCR16. Analysis of
the DNA from the parents of HUS12 revealed that the
mother also carries the T956M mutation in heterozy-
gosis. No mutations in HF1 were found in the remaining
nine patients with aHUS, by either SSCP or DNA se-
quencing analyses.
Different strategies, involving the use of monoclonal
antibodies, enzymatic digestion, or deletion mutagenesis,
have allowed the identification and characterization of
distinct functional domains in the factor H molecule,
although it has not been exactly determined which
amino acid residues are responsible for these functions
(Alsenz et al. 1985; Gordon et al. 1995; Ku¨hn et al.
1995; Jokiranta et al. 1996; Prodinger et al. 1998). Fig-
ure 1c depicts schematically some of these functional
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Table 2
Complement Profiles and Factor H Levels in Patients with aHUS
Patient







HUS2 (23) Chronic renal failure, transplanted twice Normal Normal 71.2 30 1,158
HUS3 (53) Chronic renal failure, hemodialysis Normal Low 59.2 26.3 109e
HUS5 (4) Three HUS episodes, neurological symptoms Normal Normal 112 15 350
HUS8 (12) Neurological symptoms Normal Normal 96.5 30.3 501
HUS9 (10) Two HUS episodes, neurological symptoms Normal Normal 113 23.5 286
HUS10 (10) One HUS episode Normal Normal 94.1 17 484
HUS11 (12) Transplanted twice, deceased Normal Normal 167 53 1,225
HUS12 (13) One HUS episode Normal Normal 135 27.2 821
HUS13 (10) Transplanted, hemodialysis Normal Normal 86.5 10.6 546
HUS14 (21) Cyclosporin related, chronic renal failure, transplanted Normal Normal 84 24.4 195
HUS15 (17) Cyclosporin related, chronic renal failure, transplanted Normal Normal 96.2 19.5 483
HUS16 (2) One HUS episode Normal Normal 90.8 15.5 1,052
HUS18 (10) One HUS episode Normal Normal 109 15.7 320
a Hemolytic assay using antibody-sensitized erythrocytes.
b Hemolytic assay using rabbit erythrocytes.
c Measured in EDTA-plasma samples and determined by nephelometry (Immage: Backmann). The normal ranges of concentration for C3
and C4 are 77–210 and 14–47 mg/ml, respectively.
d Quantitated by a sandwich ELISA using goat polyclonal antibodies (Quidel) and a murine polyclonal antibody (Quidel) and by semi-
quantitative western blot analyses as described elsewhere (Sa´nchez-Corral et al. 2000). The range of concentration for factor H was 170–500
mg/ml.
e Individual was demonstrated to be heterozygous for an HF1 null allele.
domains. Factor H has three binding sites for C3b—in
SCR1–SCR4, SCR6–SCR10, and SCR16–SCR20. The
C3b-binding site in SCR1–SCR4 is the only site essential
for the cofactor activity with factor I, but deletion of
any of the C3b-binding sites significantly decreases fac-
tor H binding to C3b deposited on cellular surfaces
(Sharma and Pangburn 1996). In addition, figure 1c il-
lustrates that SCR7, SCR13, and SCR16–SCR20 have
been found to contain heparin- and sialic acid–binding
sites (Pangburn et al. 1991; Blackmore et al. 1996, 1998;
Ram et al. 1998).
The T956M, W1183L, L1189R, and V1197A mu-
tations identified in this study alter the amino acid se-
quence of the factor H molecule without apparently af-
fecting the normal secretion of the protein into plasma
(table 2) (for the factor H sequence, see Entrez Nucle-
otide Sequence Search). One of these mutations lies in
SCR16, and the other three in SCR20, the most C-ter-
minal domain of factor H. There are only two other
cases of aHUS that have normal levels of factor H and
in which mutations in HF1 have been previously iden-
tified, and, most interesting, in both cases the mutations
(R1215G and R1210C) also lie in SCR20 (Warwicker
et al. 1998; Caprioli et al. 2000). The clustering of mis-
sense mutations in the SCR16–SCR20 domains of factor
H in patients with aHUS contrasts with the random
distribution of (1) HF1 mutations in individuals with
factor H deficiency (Ault et al. 1997; Warwicker et al.
1998; Buddles et al. 2000; Sa´nchez-Corral et al. 2000)
and (2) the HF1 single-nucleotide polymorphisms thus
far described (see above), strongly suggesting a geno-
type-phenotype correlation in aHUS, which points to
the involvement, in the pathogenesis of this disease, of
a specific dysfunction in the C-terminal region of fac-
tor H.
Although the relative contributions of SCR16 and
SCR20 to the functional map of factor H have not been
established, it is clear that both SCRs are part of a re-
gion that is involved in the binding to solid-phase C3b
and to negatively charged cellular structures (such as
sialic acid)—and that this region contributes significant-
ly to the capacity of factor H to control activation of
the complement system on certain cellular surfaces
(Pangburn et al. 2000). Therefore, it is likely that the
SCR16–SCR20 mutations found in patients with aHUS
result in a defective protection of cellular surfaces by
factor H. On the other hand, the T956M, W1183L,
L1189R, and V1197A mutations should not alter the
cofactor activity of factor H in the fluid phase, which is
in agreement with the normal complement activity and
C3 levels observed in our patients with aHUS. It is no-
ticeable that in patients HUS2, HUS11, and HUS12 the
levels of factor H are considerably elevated. Whether
this situation results from an increased transcription of
the HF1 gene or is a consequence of a low turnover of
the mutated protein in plasma remains to be determined.
Thus far, two types of mutations in factor H have been
observed in patients with aHUS: nullHF1 alleles resulting
in decreased levels of factor H and missense mutations in
the SCR16–SCR20 region. Interestingly, one of our pa-
tients with aHUS (i.e., HUS3) carries both an HF1 null
allele and the V1197A mutation in her only functional
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HF1 copy, which suggests that, in some cases, both de-
creased levels of factor H and mutations in SCR16–
SCR20 may be necessary to produce pathologically sig-
nificant dysfunction of factor H. In this regard, it should
be interesting to reevaluate the previously described cases
of aHUS that have decreased levels of factor H, in a search
for additional HF1 missense mutations.
As indicated above, nine of our patients with aHUS
have no mutations in HF1 and present normal levels of
factor H in plasma. Experiments to further characterize
the activity of factor H in the sera of these patients,
including the search for potential plasma components
that may interfere with the role of factor H in controlling
the surface activation of the complement system, would
be needed before involvement of factor H can be ex-
cluded from the pathogenesis of aHUS in these patients.
Our patients with aHUS who have missense mutations
in the SCR16–SCR20 region are HF1 heterozygotes,
which make difficult the purification and analysis of the
mutant factor H proteins. Functional characterization of
these mutations in recombinant factor H molecules
would be needed to confirm that, in patients with aHUS,
there is a defective control, by factor H, of the activation
of the complement system on cellular surfaces. If this
hypothesis is correct, administration of exogenous, func-
tionally active factor H may become a successful ther-
apeutic approach for a significant number of patients
with aHUS.
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